The effect of anti-PD-1/PD-L1 antibodies combined with VEGF receptor tyrosine kinase inhibitors versus bevacizumab in unresectable hepatocellular carcinoma

Overview of attention for article published in Frontiers in immunology, January 2023

Altmetric Badge

Mentioned by

twitter: 2 X users

Readers on

mendeley: 14 Mendeley

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 52,356 followers.

The effect of anti-PD-1/PD-L1 antibodies combined with VEGF receptor tyrosine kinase inhibitors versus bevacizumab in unresectable hepatocellular carcinoma https://t.co/vnnWpDKRsy https://t.co/X5xDiMUZUU

24 Jan 2023

Reply Repost Favourite

New Research: The effect of anti-PD-1/PD-L1 antibodies combined with VEGF receptor tyrosine kinase inhibitors versus bevacizumab in unresectable hepatocellular carcinoma: Introduction Immune checkpoint inhibition (ICI) plus bevacizumab (BEV)… https://t.co

23 Jan 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.